BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
BellaSeno’s 3D-printed Resorbable Scaffold
Successfully Used in Critical-Size Large Segmental Radius Bone Defect
New investigator-initiated clinical trials
BellaSeno’s resorbable tissue regeneration scaffolds to be conducted in Europe
BellaSeno Presents Novel Production Workflow
Production Workflow for Customized, 3D-Printed Bone Scaffolds
Positive Follow-Up Data
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
Granted Market Access
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
Positive Interim Data of BellaSeno’s Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants
Pectus excavatum camouflage
The first-in-human trial of soft tissue engineering to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
